Within days of TRIUMPH-1‘s full presentation at the ADA Scientific Sessions in New Orleans, Eli Lilly announced positive topline results from two additional pivotal Phase 3 trials — TRIUMPH-2 and TRIUMPH-3. Together with TRIUMPH-1 and TRIUMPH-4, these four readouts now form the most comprehensive dataset ever assembled for a single metabolic peptide across multiple disease indications simultaneously. For Australian researchers, the breadth and consistency of what has emerged in the past eight months is extraordinary. Here is the complete picture.
The TRIUMPH programme is Eli Lilly’s Phase 3 global registrational development programme for R3TA — the first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. It launched in 2023 and has enrolled more than 5,800 participants across major trials evaluating obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, and cardiovascular outcomes.
As of August 2026, four TRIUMPH trials have reported positive results:
TRIUMPH-4 (December 2025): Obesity plus knee osteoarthritis. 28.7% weight loss at 68 weeks on 12mg. Complete knee pain resolution in one in eight treated participants.
TRANSCEND-T2D-1 (March 2026): Type 2 diabetes. 16.8% weight loss at 40 weeks on 12mg, HbA1c reductions across all doses.
TRIUMPH-1 (May/June 2026): Obesity without diabetes. 28.3% weight loss at 80 weeks on 12mg. 45.3% of participants achieving 30% or greater weight loss.
TRIUMPH-2 and TRIUMPH-3 (July/August 2026): The two most recently announced trials — now the focus of this article.
Lilly plans to submit a Biologics License Application to the FDA in Q1 2027. The breadth of the TRIUMPH programme across indications means Retatrutide is being developed not as a narrow obesity drug but as a comprehensive cardiometabolic compound — a positioning that has significant implications for the Australian research community.
TRIUMPH-2 evaluated Retatrutide in adults with obesity or overweight and type 2 diabetes — the patient population where metabolic compound research is most clinically urgent globally and where the combination of weight loss and glycaemic control is most consequential.
The trial enrolled participants across all three Retatrutide doses (4mg, 9mg, 12mg) versus placebo, with the primary endpoints covering both weight reduction and glycaemic control — making it one of the most clinically comprehensive metabolic trials in the TRIUMPH programme.
Weight loss outcomes: Participants taking Retatrutide 4mg, 9mg, and 12mg lost an average of 12.7%, 19.1%, and 20.8% of body weight respectively, alongside HbA1c reductions of up to an average of 1.6%.
For context, the 20.8% weight loss at the 12mg dose in a population with type 2 diabetes — a condition that typically blunts weight loss responses to GLP-1 class compounds due to insulin resistance and related metabolic dysfunction — is a landmark figure. Approved dual agonists have achieved approximately 14-16% weight loss in comparable diabetic populations. Retatrutide’s 20.8% represents a meaningful step change.
Glycaemic control: The HbA1c reductions of up to 1.6% across all doses are clinically significant in their own right — with a higher proportion of patients treated with Retatrutide meeting HbA1c targets of below 7.0%, at or below 6.5%, and below 5.7% compared to placebo. The achievement of HbA1c below 5.7% — the threshold for normal blood glucose — in a meaningful proportion of type 2 diabetes patients is one of the most striking findings in the entire TRIUMPH dataset.
What this means for Australian researchers: Type 2 diabetes affects approximately 1.3 million Australians — one of the highest prevalence rates in the developed world. The intersection of obesity and type 2 diabetes is the single most important research target in Australian metabolic medicine. TRIUMPH-2’s data establishes Retatrutide as the most efficacious compound ever tested in this combined indication — with implications for research into insulin resistance mechanisms, beta cell function, and the relationship between weight loss magnitude and glycaemic normalisation.
The mechanistic question that TRIUMPH-2 raises for researchers is specific and important: how much of Retatrutide’s glycaemic benefit in type 2 diabetes is attributable to weight loss, and how much represents direct receptor-mediated effects on pancreatic function and hepatic glucose production independent of weight? Separating these contributions requires precisely the kind of controlled preclinical research that Australian researchers are well-positioned to conduct.
TRIUMPH-3 is the most clinically high-stakes trial in the TRIUMPH programme — evaluating Retatrutide in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. This is the population at highest acute risk from metabolic disease, and the population where the cardiovascular benefits of metabolic intervention translate most directly to reduced mortality.
In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 55.8 pounds — 22.6% of body weight — at 80 weeks.
The 22.6% weight loss in a population with established cardiovascular disease is significant for several reasons beyond the headline number. Participants in this trial are typically on multiple cardiovascular medications, have compromised baseline metabolic function, and represent a population historically excluded from or under-represented in obesity research. Achieving 22.6% weight loss in this high-risk, heavily medicated population — and doing so with the safety profile observed across the TRIUMPH programme — is a finding with direct clinical research implications.
The cardiovascular research angle: TRIUMPH-3’s significance extends well beyond weight loss into the cardiovascular outcomes research space. The SELECT trial for semaglutide established that GLP-1 receptor agonism can reduce major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity. TRIUMPH-3 is now generating the dataset that will allow researchers to investigate whether Retatrutide’s triple agonism produces cardiovascular benefits beyond what semaglutide’s single GLP-1 mechanism achieves — and whether the glucagon receptor component, with its specific effects on hepatic fat metabolism and triglyceride reduction, contributes additional cardiovascular benefit through mechanisms distinct from appetite suppression and weight loss.
In TRIUMPH-1, Retatrutide was associated with reductions of up to 41.0% in triglycerides, 24.2% in non-HDL cholesterol, 12.3 mmHg in systolic blood pressure, and 24.1cm in waist circumference at 80 weeks. These cardiometabolic markers — now replicated across the TRIUMPH programme — are precisely the parameters that cardiovascular researchers use to assess atherosclerotic risk modification. The question of whether Retatrutide’s lipid and blood pressure effects translate into hard cardiovascular event reduction is one of the most important unanswered questions in the entire dataset — and one that the dedicated cardiovascular outcomes trial will address.
For Australian cardiovascular researchers: Cardiovascular disease remains the leading cause of death in Australia. The intersection of obesity, metabolic syndrome, and cardiovascular risk is the dominant clinical challenge in Australian cardiology and metabolic medicine. TRIUMPH-3’s dataset — when fully published — will provide Australian researchers with the most comprehensive evidence base ever assembled for investigating Retatrutide’s cardiovascular research applications.
The four positive TRIUMPH readouts now available — across obesity alone, obesity plus knee osteoarthritis, obesity plus type 2 diabetes, and obesity plus established cardiovascular disease — tell a consistent and compelling story:
Consistency across populations: Retatrutide’s efficacy signal is remarkably consistent across metabolically diverse patient populations. Whether participants have diabetes, cardiovascular disease, osteoarthritis, or obesity alone, the weight loss trajectory, glycaemic improvement, and cardiometabolic marker reduction are consistent in direction if varying in magnitude. This population-wide consistency is one of the strongest signals of genuine mechanistic activity rather than population-specific effects.
The dose-response is clear across all trials: All three doses — 4mg, 9mg, 12mg — produce meaningful weight loss across all studied populations, with a clear and consistent dose-response relationship. For researchers, this well-defined dose-response curve provides a robust parameter space for designing protocols.
The glucagon receptor contribution is being validated: Each successive TRIUMPH trial adds to the evidence that Retatrutide’s triple agonism produces outcomes that exceed what dual agonists achieve in comparable populations. The mechanistic attribution of that incremental benefit to glucagon receptor co-activation — rather than to differences in study design, population, or GLP-1/GIP dosing — is the central research question that the full published TRIUMPH dataset will allow investigators to address.
The BLA submission timeline is confirmed: Lilly plans to submit a Biologics License Application to the FDA in Q1 2027. This means that by the time Australian regulatory approval could follow — typically 12-24 months after FDA approval — the full TRIUMPH dataset will be published and available for Australian researchers to build upon.
The timing of TRIUMPH-2 and TRIUMPH-3 readouts creates a specific research opportunity for Australian investigators that is worth stating directly.
The Phase 3 data is now available — but the mechanistic research that explains and extends it is still in its early stages. How does glucagon receptor co-activation specifically modify cardiovascular risk markers beyond weight loss? What are the mechanisms of glycaemic normalisation in type 2 diabetes that go beyond the weight-loss-mediated improvement in insulin sensitivity? How do Retatrutide’s three receptor targets interact at the molecular level to produce synergistic rather than simply additive effects?
These are the questions that preclinical and mechanistic research — conducted with research-grade Retatrutide in controlled laboratory settings — is best positioned to answer. Australian researchers who build protocols around these questions now will be working at the frontier of the field as the FDA submission proceeds and global clinical research interest intensifies.
New batch COAs and restock alerts, sent when they happen.
Need more information about Peps Aussie? Get in contact with us via the email below and Peps Aussie will assist you promptly.
Include your name and a relevant subject line.
Every batch we publish a third-party certificate of analysis. Get told when a new one lands, and when a sold-out peptide is back.
